U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C25H24FN3O2
Molecular Weight 417.4754
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SLV-310

SMILES

FC1=CC2=C(NC=C2C3=CCN(CCCCN4C(=O)C5=CC=CC=C5C4=O)CC3)C=C1

InChI

InChIKey=NECJNLXOJRDELU-UHFFFAOYSA-N
InChI=1S/C25H24FN3O2/c26-18-7-8-23-21(15-18)22(16-27-23)17-9-13-28(14-10-17)11-3-4-12-29-24(30)19-5-1-2-6-20(19)25(29)31/h1-2,5-9,15-16,27H,3-4,10-14H2

HIDE SMILES / InChI

Molecular Formula C25H24FN3O2
Molecular Weight 417.4754
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 11:54:35 GMT 2023
Edited
by admin
on Sat Dec 16 11:54:35 GMT 2023
Record UNII
69GK99VB9C
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
SLV-310
Common Name English
1H-ISOINDOLE-1,3(2H)-DIONE, 2-(4-(4-(5-FLUORO-1H-INDOL-3-YL)-3,6-DIHYDRO-1(2H)-PYRIDINYL)BUTYL)-
Systematic Name English
2-(4-(4-(5-FLUORO-1H-INDOL-3-YL)-3,6-DIHYDROPYRIDIN-1(2H)-YL)BUTYL)-1H-ISOINDOLE-1,3(2H)-DIONE
Systematic Name English
2-(4-(4-(5-FLUORO-1H-INDOL-3-YL)-3,6-DIHYDRO-2H-PYRIDIN-1-YL)BUTYL)ISOINDOLINE-1,3-DIONE
Systematic Name English
Code System Code Type Description
CAS
264869-71-8
Created by admin on Sat Dec 16 11:54:35 GMT 2023 , Edited by admin on Sat Dec 16 11:54:35 GMT 2023
PRIMARY
PUBCHEM
9888211
Created by admin on Sat Dec 16 11:54:35 GMT 2023 , Edited by admin on Sat Dec 16 11:54:35 GMT 2023
PRIMARY
FDA UNII
69GK99VB9C
Created by admin on Sat Dec 16 11:54:35 GMT 2023 , Edited by admin on Sat Dec 16 11:54:35 GMT 2023
PRIMARY
SMS_ID
300000041438
Created by admin on Sat Dec 16 11:54:35 GMT 2023 , Edited by admin on Sat Dec 16 11:54:35 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY
SLV 310 is a novel compound combining potent dopamine D 2 receptor antagonism with serotonin reuptake inhibition.
ACTIVE MOIETY
The antipsychotic potency of 6b was demonstrated by the fact that 6b significantly disrupted avoidance behaviour14 in a conditioned avoidance response paradigm in three independent groups of trained rats (ED50=17.5 mg/kg, po, based on the HCl salt of 6b). It can be concluded that 6b is a promising novel antipsychotic indeed, combining strong dopamine D2-receptor antagonism with SRI effects in the same dose range.